Position in ADCT
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$390,191
+$70,081 QoQ
Shares Held
104,051
+14.7% QoQ
Ownership
0.082%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 22%
Shared 0%
None 78%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026RHUMBLINE ADVISERS holds $438,094,582 across 50 Drug Manufacturers - Specialty & Generic names. ADCT ranks #36 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
1,229,009 | $145,281,153 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
122,486 | $72,631,748 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
303,820 | $40,025,246 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
1,268,203 | $30,348,097 | |
| 5 | VTRS |
Viatris Inc
|
1,941,082 | $26,224,017 | |
| 6 | ALKS |
Alkermes plc.
|
449,531 | $15,895,416 | |
| 7 | LNTH |
Lantheus Holdings, Inc.
|
194,563 | $14,757,603 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
643,856 | $13,366,450 |
All Filings in ADCT
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $390,191 | 104,051 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $320,110 | 90,683 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $401,896 | 100,474 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $274,989 | 102,608 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $157,396 | 111,629 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | $218,973 | 110,037 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $299,845 | 95,189 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $271,687 | 85,977 | Shares | Sole | 2024-08-01 | |
| No filing history on record for this holder in this stock. | ||||||